1. Home
  2. OSCR vs IOVA Comparison

OSCR vs IOVA Comparison

Compare OSCR & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oscar Health Inc.

OSCR

Oscar Health Inc.

HOLD

Current Price

$16.60

Market Cap

4.7B

Sector

Finance

ML Signal

HOLD

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$2.21

Market Cap

968.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OSCR
IOVA
Founded
2012
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Accident &Health Insurance
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7B
968.6M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
OSCR
IOVA
Price
$16.60
$2.21
Analyst Decision
Sell
Buy
Analyst Count
7
12
Target Price
$15.57
$10.36
AVG Volume (30 Days)
12.4M
9.8M
Earning Date
02-03-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$11,288,628,000.00
$250,425,000.00
Revenue This Year
$33.55
$60.94
Revenue Next Year
$3.30
$60.85
P/E Ratio
N/A
N/A
Revenue Growth
37.38
175.62
52 Week Low
$11.20
$1.64
52 Week High
$23.80
$8.56

Technical Indicators

Market Signals
Indicator
OSCR
IOVA
Relative Strength Index (RSI) 49.89 46.56
Support Level $15.53 $2.18
Resistance Level $17.17 $2.32
Average True Range (ATR) 0.90 0.12
MACD 0.09 -0.01
Stochastic Oscillator 34.35 18.11

Price Performance

Historical Comparison
OSCR
IOVA

About OSCR Oscar Health Inc.

Oscar Health Inc is a health insurance company. The company provides various insurance plans for individuals, families, and employees. Also, the company provides virtual care, doctor support, scheduling appointments, and other related services. The company provides plans in the Medicare Advantage program to adults who are age 65 and older and eligible for traditional Medicare but who instead select coverage through a private market plan.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Share on Social Networks: